Ocular Safety and Usability Study for FYB203 PFS

计划入组 30 人 · 首次发布于 2024 年 11 月 27 日

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration

计划入组 434 人 · 首次发布于 2020 年 8 月 21 日

Ocular Safety and Usability Study for FYB201 PFS

计划入组 31 人 · 首次发布于 2024 年 11 月 27 日

ARB203

FB23-2

SCD-411

Formycon's Aflibercept Biosimilar FYB203 Receives Positive CHMP Opinion for EU Approval

Formycon's Aflibercept Biosimilar FYB203 Receives Positive CHMP Opinion for EU Approval

FDA Approves Ahzantive, a Biosimilar to Eylea, for Retinal Diseases